Hiro Nakajima's journey within ASPINA America is quite remarkable. Starting as an electro-mechanical engineer in the motor division nearly three decades ago shows a strong foundation in technical expertise. His experience working on various projects in both the US and Japan likely provided him with a broad perspective and invaluable insights into different markets and cultures.
Transitioning to the role of Managing Director of the Medical Business Unit demonstrates not only his adaptability but also his leadership skills and strategic vision. Managing a business unit requires a deep understanding of the industry, market dynamics, and customer needs, all of which Nakajima seems to have mastered.
His current position as the CTO and Senior Vice President, working with the business development group to support frontier technologies, indicates a shift towards innovation and forward-thinking strategies. This role likely involves staying abreast of emerging technologies, identifying opportunities for growth and development, and guiding the company towards embracing new trends and advancements.
Overall, Nakajima's trajectory within ASPINA America showcases a blend of technical expertise, leadership capabilities, and a commitment to innovation, making him a valuable asset to the company's success.
Dr. Wendy Charles is a results-oriented digital health and research leader with 20+ years of success identifying and prioritizing strategic research needs and scoping/executing key digital research programs aligned with business objectives. Spearheading emerging technology product introductions and compliance infrastructure for healthcare and life sciences, she is known for her unique ability to approach digital health opportunities from scientific, technology, compliance, and business development perspectives. Wendy has a PhD in Clinical Science with a specialty in Health Information Technology. She serves as an independent consultant and faculty member, where she teaches the business of digital health at the University of Colorado Denver and health informatics at the University of Denver.
Noel advises start up and emerging growth clients on strategic patent portfolio development and implementation to protect their technology and achieve their business objectives, the most important objectives being market share and premium pricing. He has extensive experience working with digital health, health information technology, and medical devices companies; telecommunications companies; semiconductor; and software and Internet companies.
Shawnnah Monterrey currently is the Founder and CEO of BeanStock Ventures, a medical device product development company and an FDA accredited 510(k) review organization and medical device venture studio. Shawnnah Monterrey founded BeanStock Ventures, in 2018 following nearly a 20-year career as a technical leader responsible for developing strategies and leading complex global product development programs and functional management of software and software quality assurance departments for both startup and mature organizations with significant emphasis on the development of medical instruments, life science, diagnostics, clinical applications. Shawnnah’s tenure includes technical leadership roles at Illumina, Covidien (Medtronic), Invetech (Danaher) and Carl Zeiss Meditec. She currently is a member of NuFund and the National Institute of Health (NIH) Commercialization Readiness Pilot Special Emphasis Review Panel. Shawnnah holds an executive MBA from San Diego State University and a Bachelor’s of Science in Computer Science from USCD. She has received numerous awards and nominations since she founded BeanStock Ventures.
Bobby Edelman, a seasoned operator, mentor, and investor with a distinguished career in technology, marketing, and distribution. He played an executive role in scaling a $200 million dollar computer product and internet streaming media business, contributing to the $800 million sale of Fortune 500 company Marshall Electronics. His early internet streaming media innovation, 'Netseminar', is featured in the Amazon Book 'Opening Digital Markets'. Currently, Bobby is an active angel investor at Nufund, San Diego Angel Conference and an Advisor with The Brink. He has invested in over 100 early-stage investments focusing on private market platforms, hard tech and platform. He enjoys diving, yoga, and time with Ziggy, a Shih Tsu, and family.
I'm an angel investor and deal scout for many different funds including The Hustle Fund. I work with VCs, PE, FO, IB, HNWI. My experience ranges from mentoring startup founders, c-suite positions at multiple companies, building businesses and entrepreneurism. Throughout my years in the space, I've created several companies and had an exit in the telecom space. I currently advise five companies, two being startups as an advisory board member. My COO position is with GCN, Global Capital Network, an investor and founders conference out of Newport Beach, CA, where founders pitch to over 150+ investors during a 1 day event.
Kaye Villaflores has over 20 years of experience in program management and professional services within the life sciences and technology industry. Kaye has supported founders and product development in the life sciences industry, primarily medical devices fast-tracked to FDA approval – ranging from wearables with mobile apps, to genomic sequencing for personalized oncology and IVF treatment, to surgical instruments – all with integrated AI and cybersecurity features. Additionally, she has experience in R&D and iterative prototyping to bring to market groundbreaking, innovative solutions in software and hardware. Fun Fact: BeanStock Ventures is 1 in 7 of FDA accredited review organizations globally!
More to be announced...
The future of Biology is Digital and AI stands at the forefront of this transformative journey! We invite you to join us for an enlightening day of discovery, networking, and inspiration, where we delve into the realm of AI-powered Digital Biology and its profound influence on the future of Biotechnology, Pharmaceuticals, and Life itself!
AI Digital Biology is reshaping the life sciences economy through modeling, computational biology, omics data, and synthetic biology. It has the power to not only save lives but also mitigate pollution and maybe expedite the pace of evolution.
Come support startup companies in the AIDBio space. We extend a warm invitation to all biotech, pharma, academics, entrepreneurs, and investors to be a part of the AI Digital Biology Era. Connect with leading AI industry experts, and engage in passionate discussions, sharing your insights and perspectives with our vibrant community.
Are you ready to supercharge your innovative startup in the cutting-edge fields of Artificial Intelligence and Machine Learning? Don't miss this golden opportunity to bring your vision to life!
Pitch your startup to an audience of industry experts, colleagues, and seasoned investors to gain valuable insights and feedback, forge strategic partnerships and connections, secure vital funding for your pioneering project, and elevate your startup to the next level!
